Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT: ctDNA-guided adjuvant chemotherapy after rectal cancer surgery
NL-OMON56933Phase 3Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid and capecitabine in rectal cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Disease-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON56933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56933.